Ema on AstraZeneca and thrombosis: “rare cases, 1 in 100,000 the rate of carryovers”. Effectiveness confirmed

Get real time updates directly on you device, subscribe now.

The benefits of AstraZeneca’s Covid-19 vaccine outweigh the risks. The EMA continues to reiterate what it had already expressed several times e does not stop the administration of the AstraZeneca anti-Covid vaccine. It recognizes the relationship between the vaccine and thrombosis cases but does not impose restrictions or age limits and therefore leaves the choice of individual countries to decide on the method of administration among the population.
“The data we have at the moment does not allow us to make effective connections of risks with a specific age, neither between men and women, nor to implement specific restrictions,” said Dr. Sabine Straus, head of the Ema Pharmacovigilance Committee.

The verdict of the EMA, theEuropean Medicines Agency, Therefore “absolves” the AstraZeneca vaccine again, despite the blocking of administration on certain age groups announced in various European countries and in the world, following the blood clotting problems encountered in recent weeks on subjects who had undergone vaccination .

“We have high benefits from administering this vaccine, AstraZeneca is effective in preventing Covid and the decision we reached follows the risk analysis and the finding that they are extremely rare,” Straus stressed. “We could say that the cases of blood clots detected so far are 1 to 2 in 100 thousand or even a little more. In any case, this is not an incidence rate, but a reporting rate, or depends on the cases reported in relation to the amount of vaccines performed until this moment”.

AstraZeneca will now be required to carry out laboratory studies to try to better understand the clot system, will therefore have to analyze the existing data to assess whether they can provide further information on the risk factors, so there will be new trials and the conduct of specific epidemic studies. All this, in parallel with other studies launched directly by the EMA.

No indications have yet been issued on the possibility of “mixing” the vaccines in the case of the first and second dose. This will also depend on the availability of vaccines, however a specific assessment has not yet been made, as we are still in a data collection phase.

At the moment, what the EMA recommends is to refer to the official guidelines on treatments, avoiding the administration of heparin, an anticoagulant that could have a responsibility in cases of cerebral venous thrombosis occurring after vaccination with AstraZeneca.

As for possible similarities with the vaccine Johnson & Johnson – realized as in the case of AstraZeneca with the use of an adenovirus – at the moment There were only 3 cases of blood clots which bear some similarities to those associated with AstraZeneca, but these are extremely low numbers (3 out of 4.5 million). However, this vaccine is also being analyzed by the European Agency and is being monitored intensively.

Get real time updates directly on you device, subscribe now.

Leave A Reply

Your email address will not be published.